Mirati Therapeutics (MRTX) Stock Price, News & Analysis

Company Overview

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $58.70 to $58.70
• 50-Day Range: $58.70 to $59.28
• 52-Week Range: $27.30 to $64.41
• Volume: N/A
• Average Volume: 2.76 million shs
• Market Capitalization: $4.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.00
• Consensus Rating: Hold

Mirati Therapeutics Stock Analysis - MarketRank™

Mirati Therapeutics scored higher than 11% of companies evaluated by MarketBeat, and ranked 916th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Mirati Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Mirati Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mirati Therapeutics are expected to grow in the coming year, from ($11.39) to ($9.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mirati Therapeutics is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mirati Therapeutics is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mirati Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MRTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mirati Therapeutics does not currently pay a dividend.

Dividend Growth

Mirati Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.68

Short Interest

There is no current short interest data available for MRTX.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mirati Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.26% of the stock of Mirati Therapeutics is held by insiders.

MRTX Stock Analysis - Frequently Asked Questions

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($2.49) EPS for the quarter, topping analysts' consensus estimates of ($2.83) by $0.34. The business's quarterly revenue was up 203.7% on a year-over-year basis.

Does Mirati Therapeutics have any subsidiaries?

The following companies are subsidiaries of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirati Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH), Humana (HUM) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 11/06/2023
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MRTX
• CUSIP: N/A
• CIK: 1576263
• Web: www.mirati.com
• Phone: (858) 332-3410
• Fax: N/A
• Employees: 587
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $59.00
• High Stock Price Target: $59.00
• Low Stock Price Target: $59.00
• Potential Upside/Downside: +0.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($12.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-740,870,000.00
• Net Margins: -1,900.65%
• Pretax Margin: -1,899.99%
• Return on Equity: -82.15%
• Return on Assets: -67.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.54
• Quick Ratio: 7.40

Sales & Book Value

• Annual Sales: $12.44 million
• Price / Sales: 331.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.31 per share
• Price / Book: 3.39

Miscellaneous

• Outstanding Shares: 70,150,000
• Free Float: 67,861,000
• Market Cap: $4.12 billion
• Optionable: Optionable
• Beta: 0.77